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Background. While assisted reproductive technology (ART), including in vitro fertilization has given hope to millions of couples
suﬀering from infertility, it has also introduced countless ethical, legal, and social challenges. The objective of this paper is to
identifytheaspectsofARTthataremostrelevanttopresent-daysocietyanddiscussthemultipleethical,legal,andsocialchallenges
inherent to this technology. Scope of Review. This paper evaluates some of the most visible and challenging topics in the ﬁeld of
ART and outlines the ethical, legal, and social challenges they introduce. Major Conclusions. ART has resulted in a tectonic shift in
the way physicians and the general population perceive infertility and ethics. In the coming years, advancing technology is likely
to exacerbate ethical, legal, and social concerns associated with ART. ART is directly challenging society to reevaluate the way in
which human life, social justice and equality, and claims to genetic oﬀspring are viewed. Furthermore, these issues will force legal
systems to modify existing laws to accommodate the unique challenges created by ART. Society has a responsibility to ensure that
the advances achieved through ART are implemented in a socially responsible manner.
1.Introduction
ART is currently a commonplace technology that has suc-
cessfully treated millions of infertile couples the world over.
However, the explosion of this technology has introduced a
myriadofnewsocial,ethical,andlegalchallenges.Thispaper
evaluates some of the most visible and challenging topics in
the ﬁeld of ART and outlines the ethical, legal and social
challenges they introduce.
2. Scope of ART Utilization
Infertility has traditionally been an area of medicine in
which physicians had limited means to help their patients.
The landscape of this ﬁeld changed dramatically with
the announcement of the birth of Louise Brown in 1978
through in vitro fertilization (IVF). This historic moment
was eloquently encapsulated by Howard Jones who observed
“Eleven forty-seven p.m. Tuesday, July 25, 1978, was surely
a unique moment in the life of Patrick Steptoe. This was
the hour and minute he delivered Louise Brown, the world’s
ﬁrst baby, meticulously, lovingly, and aseptically conceived
in the laboratory, but popularly referred to as the world’s
ﬁrst test tube baby” [1]. The importance of this birth to
scientists, clinicians, and most particularly infertile patients
throughout the world cannot be overstated. In several short
decades, IVF has exploded in availability and use throughout
the world.
Worldwide, more than 70 million couples are aﬄicted
with infertility [2]. Since the ﬁrst successful IVF procedure
in 1978 [3], the use of this and related technologies has
expanded to become commonplace around the globe. Over
the past decade, the use of ART services has increased at a
rate of 5–10% annually [4, 5].
In 1996, approximately 60,000 IVF cycles were initiated
in the United States with approximately 17,000 clinical
pregnancies and 14,000 live births [6]. Currently, IVF
accounts for approximately 1% of all live births in the
United States [6]. As of 2009, 3.4 million children have been
born worldwide after ART treatment, and ART utilization is2 Obstetrics and Gynecology International
currentlyincreasingatarateof5–10%annuallyindeveloped
countries [4].
3. Reporting Regulations
The widespread use of this technology throughout the world
has prompted a desire by the public, governmental bodies,
and professional organizations to create mechanisms that
evaluate the utilization of ART. Advances in the arena of
assisted reproductive technologies (ART) are accompanied
by ethical and societal concerns. Legislation and professional
societies have attempted to address these concerns for some
time. For example, in 1986, the American Fertility Society
ﬁrst published guidelines for the ethical implementation
of ART in the United States [7]. The dynamic nature of
ART and the rapid evolution of the ﬁeld result in constant
paradigm shifts that require frequent and comprehensive
evaluation by professional organizations and society alike.
In the 1980’s, concerns surrounding ART focused on the
safe administration of gonadotropins, transparency of preg-
nancy data from clinics, and addressing economic barriers
to ART access. Some of these issues, such as reporting re-
quirements for ART pregnancy results, have also been man-
dated with legislation in many nations [8]. Furthermore,
ART reporting requirements generally include the number
of embryos transferred. This measure has been extremely
important in correlating the risk of multiple gestations with
thetransferof2ormoreembryos.However,inmanynations,
reporting regulations are not accompanied by legislation
deﬁning practice patterns. For example, in the United States,
while physicians are required to report the number of
embryos transferred in an IVF cycle, there are no laws that
state the allowed number of embryos transferred [8].
Through centralized mandatory reporting registries,
general estimates of IVF activity are available in many na-
tions. In an eﬀort to deﬁne current IVF statistics and to
make this information more transparent and available to
patients, the Fertility Clinic Success Rate and Certiﬁcation
Act of 1992 was created in the United States [8]. This
law requires clinics providing IVF in the United States to
report speciﬁc information regarding IVF cycles, including
pregnancy rates [6]. This reporting data is only reported
on IVF cycle outcomes and does not include detailed infor-
mation regarding the maternal or paternal medical history
[6]. In other countries, similar national registries exist [5],
making it possible to evaluate data from IVF cycles on both
a national and international scale. A detailed accounting for
ART reporting and regulations across the globe is available
fromtheInternationalFederationofFertilitySocieties(IFFS)
[5]. In their 2010 report, the IFFS reported ART outcomes
data from 59 countries [5].
Such laws were implemented in an attempt to ensure that
patients may be informed as to which clinics have superior
ART pregnancy results. In some instances, however, this has
led to some clinics “cherry picking” patients to improve their
overall pregnancy results. This has actually become a barrier
to receiving ART for many patients with a relatively poor
pregnancy prognosis.
4. Practice Regulations and
Multiple GestationPregnancies
Federally mandated regulations, however, are not limited
to registries. Increasingly, nations have enacted legislation
that deﬁnes the parameters for acceptable practice of ART.
The transfer of multiple embryos in a single cycle increases
the rates of multiple births [9]. Because of the increased
social costs and health risks associated with multiple births,
legislationorguidelinesfromprofessionalsocietieshavebeen
introduced in many countries restricting the number of
embryos that may be transferred per IVF cycle in an eﬀort
to limit the incidence of multiple gestations [9–11]. Indeed,
a study in the United Kingdom found that the total health
care system costs following a singleton birth were £3313,
£9122 following a twin birth and £32,354 following a triplet
birth [9]. Additionally, the health risks, both to the mother
and the infant, increase dramatically with increasing number
of infants [9]. In the United States in 2007, the number of
embryos transferred per cycle ranged from 2.2 in women
under 35 to 3.1 in women over 40 years of age (CDC).
Multiple birth rates in the United States in 2007 ranged from
approximately 35% in women under 35 to 15% in women
over the age of 40 [12]. In Europe, the approximate number
of embryos transferred in the year 2006 was one (22%), two
(57%), three (19%), or four (1.6%) [13]. In 2007, 79.2% of
European births were singletons, with a twin rate of 19.9%
and a triplet rate of 0.9% [5].
Pregnancy rates associated with IVF are high compared
to those seen in the early days of the procedure. The current
eﬃciency of IVF is more cost eﬀective and eﬃcacious in
achievingpregnancythanothermodalities,suchasinjectable
gonadotropins coupled with intra uterine insemination
(IUI), which traditionally some have preferred [14]. The
increased eﬃciency of IVF has also resulted in an increased
rate of multiple gestations. Recent data suggests that single
embryo transfer, coupled with subsequent frozen embryo
transfer, results in equivalent pregnancy rates compared with
the transfer of multiple embryos, without an increase in
multiple pregnancy rates [11]. Additionally, single embryo
transfer would inherently decrease maternal and infant
health risks associated with multiple gestation pregnancies
[9]. Therefore, a trend toward single embryo transfer is likely
to increase in the future.
Variability of legislation regulating IVF exists in diﬀerent
countries and even states/provinces within a single nation
[6]. For example, in an eﬀort to minimize multiple gestation
pregnancies resulting from ART, some laws place limits on
the number of embryos that may be transferred, cryopre-
served,orfertilizedperIVFcycle[5,6,15,16].Insomecases,
theseregulationsorﬁscalpressuresresultincouplestraveling
across international border to obtain treatments that are
unavailableintheirnativecountry[17].Thispractice,known
as cross-border reproductive care (CBRC), is thought to
accountforasmuchas10%ofthetotalIVFcyclesperformed
worldwide [17, 18].Obstetrics and Gynecology International 3
5. FinancialAspectfor IVFTreatment
Perhaps one of the most obvious ethical challenges sur-
rounding ART is the inequitable distribution of access to
care. The fact that signiﬁcant economic barriers to IVF
exist in many countries results in the preferential availability
of these technologies to couples in a position of ﬁnancial
strength [19]. The cost of performing ART per live birth
varies among countries [4]. The average cost per IVF cycle
in the United States is USD 9,266 [20]. However, the cost
per live birth for autologous ART treatment cycles in the
United States, Canada, and the United Kingdom ranged
from approximately USD 33,000 to 41,000 compared to
USD 24,000 to 25,000 in Scandinavia, Japan, and Australia
[14]. The total ART treatment costs as a percentage of total
healthcare expenditures in 2003 were 0.06% in the United
States,0.09%inJapan,and0.25%inAustralia[4].Somehave
maintained that the cost for these cycles pales in comparison
to the social advantagesyielded bythe addition of productive
members of society [21]. This is especially true in societies
that have a negative or ﬂat population growth rate coupled
with an aging population [21].
The funding structure for IVF/ART is highly variable
among diﬀerent nations. For example, no federal govern-
ment reimbursement exists for IVF in the United States,
although certain states have insurance mandates for ART [4,
19, 22]. Many other countries provide full or partial coverage
through governmental insurance [4, 9]. In many instances,
long waiting times for IVF through these government pro-
gramsencouragecouplestoseektreatmentinprivatefertility
centers that accept remuneration directly from the patients
[4, 23, 24]. In the United Kingdom, for example, only
approximately 25% of all IVF cycles performed are funded
by the National Health Service [9].
6.PreimplantationGeneticTesting
Preimplantation genetic screening (PGS) and diagnosis
(PGD) oﬀer the unique ability to characterize the genetic
composition of embryos prior to embryo transfer. Given the
recent successes of these technologies, the broader imple-
mentation of this technology in the future is likely. Although
controversial, using PGD to choose embryos solely on the
basis of gender is currently being practiced [25, 26]. Sex
selection in the proper setting may oﬀer a substantial health
beneﬁt. For example, choosing to transfer only embryos of a
certain sex may confer a therapeutic beneﬁt if used to avoid
a known sex linked disorder. However, sex selection PGD
purely for the preference of the parents could conceivably,
if practiced on a large scale, skew the gender proportions in
certain nations where one gender is culturally preferred.
In the near future, with reﬁnements in microarray
technology and the deﬁning of genetic sequences associated
with certain physical characteristics, it is conceivable that
speciﬁc physical or mental characteristics may be evaluated
to guide the decision as to which embryos to transfer. This
possibility raises concerns on both ethical and practical
levels. Of more concern is the possibility that in the future,
technology will permit the manipulation of genetic material
withinanembryo.Rigorouspublicandscientiﬁcoversightof
these technologies is vital to ensure that scientiﬁc advances
are tempered with the best interests of society in mind.
7. Fertility Preservation
Female fertility is well documented to decrease with age
[27, 28]. Consequently, much research has been conducted
aimed at preserving female fertility before advanced age is
realized. Additionally, fertility preservation for individuals
aﬄicted with cancer has important implications as often
the chemotherapeutic agents used to treat cancer are toxic
to the ovary and result in diminished ovarian reserve and
reduced fertility. While techniques for freezing sperm and
embryos are well established, techniques for freezing oocytes
and ovarian tissue are still considered experimental [29].
Multiple techniques including oocyte cryopreservation and
preservation of strips of ovarian cortex with subsequent
reimplantation and stimulation have been described, with
some pregnancy success [30–33]. Fertility preservation for
cancer patients using in vitro maturation (IVM), oocyte
vitriﬁcation and the freezing of intact human ovaries with
their vascular pedicles have also been reported [34]. As of
2008, more than 5 babies had been delivered through IVF
following ovarian tissue transplantation [35]. Many have
suggested that, prior to being treated for cancer, women
should be oﬀered fertility preservation measures as outlined
above [34].
Recently, several laboratories have demonstrated the
ability to successfully cryopreserve oocytes following an IVF
cycle. These developments have profound implications. As
the birth control pill gave women the ability to prevent
pregnancy, oocyte cryopreservation may give women the
ﬂexibility to preserve their fertility potential, starting at a
young age, while postponing childbearing. However, as this
technology at the present time in many countries is generally
only available to those with ﬁnancial means. This poses
ethical and social issues that will certainly see more attention
in the future.
8. GameteDonation
The use of donor gametes, either in the form of donor sperm
or donor oocytes, is commonplace in ART. The use of donor
sperm can be traced to the 1800’s [36]. In the mid 1980s,
oocyte donation was introduced [36]. In recent years, issues
surrounding the use of donor gametes have become increas-
ingly visible [37]. Women donating oocytes must undergo
IVF. Due to the inherent medical risks associated with IVF,
including ovarian hyperstimulation syndrome and surgical
risks, a central concern of allowing women to be oocyte
donors includes adequate informed consent [37]. Consent,
in addition to outlining these medical risks, should include
counseling regarding the emotional beneﬁts and risks of
donation with an emphasis that long-term data regarding
these risks are lacking [37]. Additionally, it is considered an
ethical prerequisite that oocyte donors participate voluntar-
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expressed concern that ﬁnancial compensation of oocyte
donors may lead to exploitation as women may proceed with
oocyte donation against their own best interests, given the
inherent medical risks involved [39]. The concept of com-
modiﬁcation, that any “buying or selling” of human gametes
isinherentlyimmoral,isanadditionalargumentusedagainst
remunerating women serving as oocyte donors [39]. Due
to the substantial controversy surrounding oocyte donation,
especially the amount of ﬁnancial compensation may be
given to an oocyte donor, federal regulations governing this
practice are constantly evolving and diﬀer substantially from
country to country [39].
Another ethical and legal issue surrounding the use
of donated gametes is to what extent the anonymity of
the donor should be preserved. The issue of anonymity as
it relates to gamete and embryo donation is emotionally
charged. Indeed, the ability of human beings to know their
genetic roots is universally important, at the core of self
identity. Either egg and sperm donors may choose to or not
to be anonymous, though the vast majority in both groups
generally chooses anonymity [40]. The American Society for
Reproductive Medicine has identiﬁed four levels of gamete
donor information sharing depending on the wishes of the
donor and recipient parties [37]. Recently, however, there
is, increasing consideration of the rights of oﬀspring as it
relates to donor gametes and anonymity [40]. Advocates for
allowing either gamete donors or their oﬀspring to break
anonymity cite the medical advantages of sharing medical
information with their genetic oﬀspring, in the case of the
donor, or learning about their genetic history directly, in the
case of oﬀspring [41, 42]. Others simply argue that both
donors and oﬀspring have an inherent right to meet and
develop a relationship [43]. Recent court rulings suggest
that these rights will become more visible in the future.
For example, in the British case Rose v Secretary of State
for Health [2002] EWHC 1593, the court ruled that based
on the Human Rights Act, donor oﬀspring could obtain
information about their genetic parents despite previously
established anonymity [43]. The ethical and legal issues
surrounding anonymity and gamete donation are sure to be
a centrally debated issues within the ﬁeld of ART for the
foreseeable future.
9. Embryo Donation
IVF cycles often result in couples transferring several embry-
os and cryopreserving other embryos produced by the cycle,
presumptively for the purpose future pregnancy. However,
in many instances, these surplus embryos are never used
by the genetic parents and therefore are stored indeﬁnitely
[44]. The number of such embryos stored internationally is
surprisingly high. In the United States alone, it is estimated
thatover400,000embryosarecurrentlycryopreserved,many
of which will not be used by their genetic parents [44]. The
ethical and moral issues surrounding how to deal with these
surplus embryos have been the source of much debate. In
general, four possible fates for these embryos exist [44]:
(1) thawing and discarding,
(2) donating to research,
(3) indeﬁnite storage,
(4) donating the embryos to another couple for the pur-
poses of uterine transfer.
All of these strategies have staunch supporters and de-
tractors. Not surprisingly, there are a myriad of laws in
diﬀerent countries governing many aspects of how a human
embryothathasbeencryopreservedmaybehandled[44,45].
The use of embryos for the purpose of research, speciﬁcally
as it relates to human stem cells, has also been a source of
ﬁerce debate internationally and has resulted in substantial
regulation that varies substantially from nation to nation
[46–49].
10.SurrogacyandGestationalCarriers
Another topic of ethical, social, and legal debate surrounds
the use of surrogacy and gestational carriers. Surrogacy is
deﬁned as a woman who agrees to carry a pregnancy using
her own oocytes but the sperm of another couple and
relinquish the child to this couple upon delivery [50]. A ges-
tationalcarrier,bycontrast,involvesacouplewhoundergoes
IVF with their genetic gametes and then places the resultant
embryo in another woman’s uterus, the gestational carrier,
who will carry the pregnancy and relinquish the child to this
couple upon delivery [50]. Currently, the use of gestational
carriers is far more common than that of surrogates [50].
As with donor gametes, surrogates and gestational car-
riers are subject to signiﬁcant medical and emotional risks
from carrying a pregnancy and undergoing a delivery [50].
As such, extensive counseling and meticulous informed
consent are required [50]. Some also are concerned that the
use of surrogates and gestational carriers is a form of “child
selling” or the “sale of parental rights” [51]. Additionally, the
rights of the surrogate or gestational carrier to not relinquish
the infant following deliver are not well described [50]. In
fact, legal precedent in some states within the United States
has actually upheld the right of a birth mother, regardless of
genetic relation to the child, to retain parental rights despite
theexistenceofapreexistinggestationalcarriercontract[50].
Another central concern surrounding the use of surro-
gates and gestational carriers is the possibility that ﬁnancial
pressures could lead to exploitation and commoidiﬁcation
of the service [50–53]. The mean compensation for a ges-
tational carrier in the United State in 2008 was estimated at
approximately $20,000 [50]. In contrast, a gestational carrier
in India receives an average of $4,000 for the same service
[52]. Regulation of surrogates and gestational carriers varies
widely from nation to nation and even within regions of
individual countries [50, 52–56]. Due to these ﬁnancial and
legal considerations, international surrogacy has emerged as
an emerging industry, especially in developing nations [52].
This practice has exacerbated the already diﬃcult ethical
and legal issues surrounding gestational carriers [52]. At the
present time, issues surrounding issues of individual rights,
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of international gestational carriers, and even fair trade are
largely unresolved internationally [52, 55].
11. Possible DeleteriousEffects of ART
There are questions that remain outstanding regarding the
use of IVF. Conﬂicting data exists about the risks of IVF
on the developing embryo. Multiple studies have failed to
ﬁnd a clinically relevant association between IVF or embryo
cryopreservation and adverse maternal or fetal eﬀects [57–
59]. Other studies have suggested that infants of IVF preg-
nancies may be at a small but statistically signiﬁcant in-
creased risk for rare epigenetic and other abnormalities [60–
62].
Despite this controversy, there is a general consensus that
IVF confers a small but measurable increased risk for
a variety of congenital abnormalities including anatomic
abnormalities and imprinting errors as compared to the
general population [63]. Some maintain, however, that this
is secondary to an increased baseline risk for these problems
in the population of infertile patients [63]. Regardless of the
cause, this small increased risk, while statistically signiﬁcant
with extremely large sample sizes, will likely not be a
powerful enough factor to dissuade infertile couples from
pursuing parenthood through IVF.
12. Conclusion
ART has emerged as one of the most widely adopted and
successful medical technologies in the last century. While
giving hope to millions of couples suﬀering from infertility,
ART also has presented new ethical, legal, and social ques-
tions that society must address. Many countries have taken
steps to regulate certain aspects of ART. Speciﬁcally, what
regulations and laws should be in place for ART reporting,
social inequities that may arise from ﬁnancial barriers to
ART, genetic testing, emerging laboratory techniques that
have improved embryo and gamete survival when cryopre-
served, and an individual’s right to their genetic oﬀspring in
the setting of gamete or embryo donation are aspects of ART
which will become increasingly controversial and debated
into the future.
However, the lion’s share of ethical and legal questions
that exist surrounding ART have yet to be resolved. Society
must reconcile how to fund ART in a responsible and equi-
table manner to increase access to care. Additionally, the
myriadofunresolvedissuessurroundinggameteandembryo
donation must be addressed in greater detail in future social
and legal dialogues.
ART is a ﬁeld that is dynamic and ever changing. In areas
of ART such as preimplantation genetics, new technologies
continuallychangethecapabilitiesofART.Duetotherapidly
evolvingnatureoftheART,legislationisoftenunabletokeep
pace and address all of the ethical and legal issues that are
constantly emerging in the ﬁeld. It is therefore incumbent
upon physicians to continually monitor these issues and
ensure that ART technologies are oﬀered and delivered in
a manner that balances patient care with social and moral
responsibility.
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